Evidence map›Paper›PMID 31752695›Full record

ArticleBMC gastroenterology2019

Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study.

Satoshi Motoya, Hiroki Tanaka, Tomoyoshi Shibuya, Taro Osada, Takayuki Yamamoto, Hitoshi Hongo, Chiemi Mizuno, Daisuke Saito, Nobuo Aoyama, Toshihisa Kobayashi and 5 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Satoshi MotoyaIBD Center, Sapporo Kosei General Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo, Hokkaido, 060-0033, Japan.
Hiroki TanakaIBD Center, Sapporo Kosei General Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo, Hokkaido, 060-0033, Japan. hirokit@mtc.biglobe.ne.jp.
Tomoyoshi ShibuyaDepartment of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8431, Tokyo, Japan.
Taro OsadaDepartment of Gastroenterology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, 279-0021, Chiba, Japan.
Takayuki YamamotoDepartment of Surgery & Inflammatory Bowel Disease Center, Yokkaichi Hazu Medical Center, 10-8 Hazuyamacho, Yokkaichi, 510-0016, Mie, Japan.
Hitoshi HongoFujita Gastroenterological Hospital, 17-36 Matsubaracho, Takatsuki, 569-0086, Osaka, Japan.
Chiemi MizunoDepartment of Gastroenterology and Hepatology, Saiseikai Suita Hospital, 1-2 Kawazonocho, Suita, 564-0013, Osaka, Japan.
Daisuke SaitoThe Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, 181-8611, Tokyo, Japan.
Nobuo AoyamaGastrointestinal Endoscopy and IBD Center, Aoyama Medical Clinic, 3-3-19 Tamondori, Chuo-ku, Kobe, 650-0015, Hyogo, Japan.
Toshihisa KobayashiDepartment of Gastroenterology, Hakodate Goryoukaku Hospital, 38-3 Goryokakucho, Hakodate, 040-8611, Hokkaido, Japan.
Hiroaki ItoKinshukai Infusion Clinic, 3-1 Ofukacho, Kita-ku, Osaka, 530-0011, Osaka, Japan.
Satoshi TanidaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Aichi, Japan.
Masanori NojimaCenter for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan.
Seiichiro KokumaMedical affairs, JIMRO Co., Ltd, 351-1 Nishiyokote, Takasaki, 370-0021, Japan.
Eiji HosoiMedical affairs, JIMRO Co., Ltd, 351-1 Nishiyokote, Takasaki, 370-0021, Japan.
JIMRO (Japan) · JPSapporo Kosei General Hospital · JPHakodate National Hospital · JPJuntendo University · JPJuntendo University Urayasu Hospital · JPKyorin University · JPNagoya City University · JPSaiseikai Suita Hospital · JPThe University of Tokyo · JPYokkaichi Social Insurance Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe available information on granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease (IBD) under special situations remains unclear. We conducted a retrospective, multicentre cohort study to evaluate the safety and effectiveness of GMA in patients with IBD under special situations.

methodsThis study included patients with ulcerative colitis (UC) or Crohn's disease who had at least one special situation feature and who had received GMA between November 2013 and March 2017. The incidence of adverse events (AEs) was compared in relation to the special situation, and patient background factors related to an AE were identified. For patients with UC, clinical remission was defined as a partial Mayo score of ≤2.

resultsA total of 437 patients were included in this study. The incidence of AEs among the elderly patients (11.2%) was similar in all patients (11.4%), whereas the incidences of AEs in patients on multiple immunosuppressant medications (15.2%), patients with anaemia (18.1%) and paediatric/adolescent patients (18.9%) were higher than that in all patients (11.4%). In multivariate analysis, anaemia and concomitant immunosuppressant medications were independently associated with the incidence of AEs. Clinical remission was achieved in 46.4% of the patients with UC.

conclusionsThe incidence of AEs in the elderly patients was not higher than that in all patients, whereas the incidence of AE was higher in patients with anaemia and those on multiple immunosuppressant medications than that in all patients. GMA is a safe treatment option in elderly patients with IBD.

Indexed as

Adrenal Cortex HormonesAge FactorsAnemiaBlood Component RemovalColitis, UlcerativeCrohn DiseaseGranulocytesHumansImmunosuppressive AgentsMonocytesRemission InductionRetrospective StudiesRisk FactorsTreatment OutcomeAdrenal Cortex HormonesImmunosuppressive AgentsAnaemiaCrohn’s diseaseElderly patientGMAGranulocyte and monocyte adsorptive apheresisImmunosuppressantInflammatory bowel diseasePaediatric patientSpecial situationUlcerative colitis

Identifiers

PMID31752695
PMCPMC6873503
OpenAlexW2990907054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.